成人住院患者的临床特征与实验室确诊的 COVID-19 肺炎。

Clinical characteristics of adult patients hospitalized with laboratory-confirmed COVID-19 pneumonia.

机构信息

Infectious Diseases and Clinical Microbiology, Istanbul Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey.

出版信息

J Infect Chemother. 2021 Feb;27(2):306-311. doi: 10.1016/j.jiac.2020.10.020. Epub 2020 Oct 23.

DOI:10.1016/j.jiac.2020.10.020

PMID:33191111

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7584418/

Abstract

BACKGROUND

The clinical spectrum of COVID-19 has a great variation from asymptomatic infection to acute respiratory distress syndrome and eventually death. The mortality rates vary across the countries probably due to the heterogeneity in study characteristics and patient cohorts as well as treatment strategies. Therefore, we aimed to summarize the clinical characteristics and outcomes of adult patients hospitalized with laboratory-confirmed COVID-19 pneumonia in Istanbul, Turkey.

METHODS

A total of 722 adult patients with laboratory-confirmed COVID-19 pneumonia were analyzed in this single-center retrospective study between March 15 and May 1, 2020.

RESULTS

A total of 722 laboratory-confirmed patients with COVID-19 pneumonia were included in the study. There were 235 (32.5%) elderly patients and 487 (67.5%) non-elderly patients. The most common comorbidities were hypertension (251 [34.8%]), diabetes mellitus (198 [27.4%]), and ischemic heart disease (66 [9.1%]). The most common symptoms were cough (512 [70.9%]), followed by fever (226 [31.3%]), and shortness of breath (201 [27.8%]). Lymphocytopenia was present in 29.7% of the patients, leukopenia in 12.2%, and elevated CRP in 48.8%. By the end of May 20, 648 (89.7%) patients had been discharged and 60 (8.5%) patients had died. According to our study, while our overall mortality rate was 8.5%, this rate was 14.5% in elderly patients, and the difference was significant.

CONCLUSIONS

This case series provides characteristics and outcomes of sequentially adult patients hospitalized with laboratory-confirmed COVID-19 pneumonia in Turkey.

摘要

背景

COVID-19 的临床谱从无症状感染到急性呼吸窘迫综合征，最终死亡，变化很大。由于研究特征和患者队列以及治疗策略的异质性，各国的死亡率有所不同。因此，我们旨在总结在土耳其伊斯坦布尔因实验室确诊的 COVID-19 肺炎住院的成年患者的临床特征和结局。

方法

在 2020 年 3 月 15 日至 5 月 1 日期间，对这家单中心回顾性研究中的 722 例经实验室确诊的 COVID-19 肺炎成年患者进行了分析。

结果

共有 722 例经实验室确诊的 COVID-19 肺炎患者纳入本研究。有 235 例（32.5%）为老年患者，487 例（67.5%）为非老年患者。最常见的合并症是高血压（251 例[34.8%]）、糖尿病（198 例[27.4%]）和缺血性心脏病（66 例[9.1%]）。最常见的症状是咳嗽（512 例[70.9%]），其次是发热（226 例[31.3%]）和呼吸急促（201 例[27.8%]）。淋巴细胞减少症见于 29.7%的患者，白细胞减少症见于 12.2%，C 反应蛋白升高见于 48.8%。截至 2020 年 5 月 20 日，648 例（89.7%）患者已出院，60 例（8.5%）患者死亡。根据我们的研究，虽然我们的总死亡率为 8.5%，但老年患者的死亡率为 14.5%，差异有统计学意义。